$Portola制药(PTLA)$ 厉害啊

Of the seven analysts tracking Portola Pharmaceuticals in January 2019, three of them recommended a “strong buy,” two analysts recommended a “buy” rating, and two analysts recommended a “hold” rating.

On January 7, 2019, the company had a consensus 12-month target price of $35.83, which represents a ~84.88% return on investment over the next 12 months.